Glenmark Pharmaceuticals Introduces GLIPIQ® Semaglutide in India

Glenmark Pharmaceuticals has launched GLIPIQ® (semaglutide) in India for Type 2 Diabetes Mellitus (T2DM). The new treatment aims to significantly enhance affordability for GLP-1 therapy, with weekly costs starting at ₹325. GLIPIQ® will be available in both vial and pre-filled pen formats.

Key Developments

Glenmark Pharmaceuticals announced the launch of GLIPIQ® (semaglutide) in India on March 21, 2026, for managing Type 2 Diabetes Mellitus. The company stated the drug's introduction is set to establish a new benchmark for GLP-1 therapy affordability. Weekly costs for GLIPIQ® vials will start at ₹325, with prices extending up to ₹440. The medication comes in 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL strengths. To support patients, Glenmark also launched a program called 'Sankalp' to help with starting the therapy and encourage long-term adherence.

Why This Launch Matters

India faces a significant diabetes burden, making advanced treatments like GLP-1 agonists essential but often out of reach due to cost. Glenmark's launch directly addresses this gap by providing a more affordable option, aiming to democratize access to a therapy class proven effective for blood sugar control and weight management. The timing is notable as the Indian semaglutide market is expected to grow substantially after patent expirations, signaling increased competition and greater affordability.

Background on the Market

The launch follows the expiration of semaglutide's primary patent in India on March 20, 2026, paving the way for generic competition. This has prompted several Indian pharmaceutical companies, such as Sun Pharma, Dr. Reddy's Laboratories, and Mankind Pharma, to prepare for or begin their own semaglutide product introductions. Glenmark Pharmaceuticals, a long-standing company in India since 1977, has a strong focus on diabetes and offers a wide range of generic and specialty medications. The market for GLP-1 receptor agonists in India is already seeing strong growth, with further significant expansion anticipated.

Impact on Patients and Market

Indian patients with Type 2 Diabetes now have access to a crucial GLP-1 therapy at a much lower cost. Glenmark Pharmaceuticals enters a fast-growing but highly competitive Indian semaglutide market, aiming to secure market share through its competitive pricing. GLIPIQ®'s introduction may lead other companies to adjust their pricing and strategies, contributing to a more accessible treatment environment. The 'Sankalp' program is intended to improve patient results by enhancing therapy initiation and adherence, which is vital for managing chronic conditions.

Potential Risks and Challenges

Glenmark Pharmaceuticals has previously faced regulatory scrutiny from the USFDA, including warning letters related to manufacturing at its Indore, Colvale (Goa), and Pithampur facilities. Although the company has indicated these issues do not affect current supplies or revenue, continued compliance is important for its global operations. The Indian semaglutide market is rapidly becoming crowded with new domestic and international competitors post-patent expiry, leading to fierce price competition and potential pressure on profit margins. The speed at which GLIPIQ® gains market adoption and physician acceptance, especially alongside other diabetes and weight-management options, will be critical for its success.

Competitive Landscape

GLIPIQ® enters a market previously dominated by innovators like Novo Nordisk (Ozempic, Wegovy). Competitors including Sun Pharma, Dr. Reddy's Laboratories, and Mankind Pharma are also launching or preparing their own generic semaglutide products to gain early market share. Companies like Lupin foresee significant market changes due to this influx of generic options.

Market Figures and Context

The India semaglutide market is projected to reach US$347.5 million by 2035, with an expected compound annual growth rate (CAGR) of 17.8% between 2025 and 2035. The India GLP-1 receptor agonist market was valued at USD 110.55 million in 2024 and is forecast to grow at a CAGR of 34.3% from 2025 to 2030. For comparison, typical monthly costs for oral antidiabetic drugs in India range from ₹500 to ₹3,000, while insulin treatments can cost ₹1,500 to ₹5,000 monthly.

What to Watch Next

Investors will monitor GLIPIQ®'s market uptake, sales performance, and Glenmark's success in gaining traction against strong competition. The effectiveness of Glenmark's 'Sankalp' patient support program in driving adherence and improving outcomes will also be closely watched. Key regulatory developments from bodies like the USFDA regarding Glenmark's manufacturing facilities will remain an important area of focus. The pricing strategies and market penetration of rival generic semaglutide products will shape overall price trends and market dynamics. Glenmark's future pipeline developments in diabetes and its R&D effectiveness will be crucial for its long-term growth.